The Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2030, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.

Supplemental cash flow information related to operating leases is as follows (dollars in thousands):

	Nine Months Ended
	September 30, 2019
Cash payments for operating leases	$	2,372
Right-of-use assets obtained in exchange for operating lease obligations		12,974

	September 30, 2019
Weighted-average remaining lease term	9.6 years
Weighted-average discount rate		9.0	%

Future minimum non-cancelable payments under operating leases as of September 30, 2019, were as follows (in thousands):

	Operating Leases
Remainder of 2019	$	854
2020		3,114
2021		3,139
2022		2,768
2023		2,644
Thereafter		18,701
Total future lease payments		31,220
Less imputed interest		11,170
Present value of lease liabilities	$	20,050

During the three months ended September 30, 2019 and 2018, the Company recorded operating lease expenses of $0.8 million and $0.3 million, respectively. During the nine months ended September 30, 2019 and 2018 the Company recorded operating lease expenses of $2.3 million and $1.0 million, respectively. As of September 30, 2019, the Company had no leases that have not yet commenced.

The Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company.